ID   AKT1_HUMAN              Reviewed;         480 AA.
AC   P31749; B2RAM5; B7Z5R1; Q9BWB6;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 2.
DT   10-MAY-2017, entry version 213.
DE   RecName: Full=RAC-alpha serine/threonine-protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Protein kinase B;
DE            Short=PKB;
DE   AltName: Full=Protein kinase B alpha;
DE            Short=PKB alpha;
DE   AltName: Full=Proto-oncogene c-Akt;
DE   AltName: Full=RAC-PK-alpha;
GN   Name=AKT1; Synonyms=PKB, RAC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CATALYTIC ACTIVITY.
RX   PubMed=1851997; DOI=10.1073/pnas.88.10.4171;
RA   Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A.;
RT   "Molecular cloning and identification of a serine/threonine protein
RT   kinase of the second-messenger subfamily.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:4171-4175(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11508278; DOI=10.1007/s001250100577;
RA   Matsubara A., Wasson J.C., Donelan S.S., Welling C.M., Glaser B.,
RA   Permutt M.A.;
RT   "Isolation and characterization of the human AKT1 gene, identification
RT   of 13 single nucleotide polymorphisms (SNPs), and their lack of
RT   association with Type II diabetes.";
RL   Diabetologia 44:910-913(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Adrenal gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 63-480 (ISOFORM 1), FUNCTION, CATALYTIC
RP   ACTIVITY, AND TISSUE SPECIFICITY.
RC   TISSUE=Foreskin;
RX   PubMed=1718748; DOI=10.1111/j.1432-1033.1991.tb16305.x;
RA   Coffer P.J., Woodgett J.R.;
RT   "Molecular cloning and characterisation of a novel putative protein-
RT   serine kinase related to the cAMP-dependent and protein kinase C
RT   families.";
RL   Eur. J. Biochem. 201:475-481(1991).
RN   [8]
RP   ERRATUM, AND SEQUENCE REVISION.
RX   PubMed=1533586;
RA   Coffer P.J., Woodgett J.R.;
RL   Eur. J. Biochem. 205:1217-1218(1992).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF CREB1.
RX   PubMed=9829964; DOI=10.1074/jbc.273.49.32377;
RA   Du K., Montminy M.;
RT   "CREB is a regulatory target for the protein kinase Akt/PKB.";
RL   J. Biol. Chem. 273:32377-32379(1998).
RN   [10]
RP   ENZYME REGULATION, AND PHOSPHORYLATION AT SER-473.
RX   PubMed=9736715; DOI=10.1073/pnas.95.19.11211;
RA   Delcommenne M., Tan C., Gray V., Rue L., Woodgett J.R., Dedhar S.;
RT   "Phosphoinositide-3-OH kinase-dependent regulation of glycogen
RT   synthase kinase 3 and protein kinase B/AKT by the integrin-linked
RT   kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11211-11216(1998).
RN   [11]
RP   MUTAGENESIS OF THR-308 AND SER-473, AND PHOSPHORYLATION AT THR-308 AND
RP   SER-473.
RX   PubMed=8978681;
RA   Alessi D.R., Andjelkovic M., Caudwell F.B., Cron P., Morrice N.,
RA   Cohen P., Hemmings B.A.;
RT   "Mechanism of activation of protein kinase B by insulin and IGF-1.";
RL   EMBO J. 15:6541-6551(1996).
RN   [12]
RP   FUNCTION, ENZYME REGULATION, AND PHOSPHORYLATION AT THR-308 BY PDPK1.
RX   PubMed=9512493; DOI=10.1042/bj3310299;
RA   Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.;
RT   "Activation of protein kinase B beta and gamma isoforms by insulin in
RT   vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro:
RT   comparison with protein kinase B alpha.";
RL   Biochem. J. 331:299-308(1998).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF FOXO1.
RX   PubMed=10358075; DOI=10.1074/jbc.274.24.17179;
RA   Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P.;
RT   "Phosphorylation of the transcription factor forkhead family member
RT   FKHR by protein kinase B.";
RL   J. Biol. Chem. 274:17179-17183(1999).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF RAF1, AND INTERACTION WITH RAF1.
RX   PubMed=10576742; DOI=10.1126/science.286.5445.1741;
RA   Zimmermann S., Moelling K.;
RT   "Phosphorylation and regulation of Raf by Akt (protein kinase B).";
RL   Science 286:1741-1744(1999).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF BAD, AND INTERACTION WITH BAD AND PKN2.
RX   PubMed=10926925; DOI=10.1074/jbc.M001753200;
RA   Koh H., Lee K.H., Kim D., Kim S., Kim J.W., Chung J.;
RT   "Inhibition of Akt and its anti-apoptotic activities by tumor necrosis
RT   factor-induced protein kinase C-related kinase 2 (PRK2) cleavage.";
RL   J. Biol. Chem. 275:34451-34458(2000).
RN   [16]
RP   INTERACTION WITH MTCP1; TCL1A AND TCL1B.
RX   PubMed=10983986; DOI=10.1016/S1097-2765(00)00039-3;
RA   Laine J., Kuenstle G., Obata T., Sha M., Noguchi M.;
RT   "The protooncogene TCL1 is an Akt kinase coactivator.";
RL   Mol. Cell 6:395-407(2000).
RN   [17]
RP   INTERACTION WITH TCL1A.
RX   PubMed=10716693; DOI=10.1073/pnas.97.7.3028;
RA   Pekarsky Y., Koval A., Hallas C., Bichi R., Tresini M., Malstrom S.,
RA   Russo G., Tsichlis P., Croce C.M.;
RT   "Tcl1 enhances Akt kinase activity and mediates its nuclear
RT   translocation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3028-3033(2000).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF MAP3K5, AND INTERACTION WITH MAP3K5.
RX   PubMed=11154276; DOI=10.1128/MCB.21.3.893-901.2001;
RA   Kim A.H., Khursigara G., Sun X., Franke T.F., Chao M.V.;
RT   "Akt phosphorylates and negatively regulates apoptosis signal-
RT   regulating kinase 1.";
RL   Mol. Cell. Biol. 21:893-901(2001).
RN   [19]
RP   INTERACTION WITH THEM4, AND SUBCELLULAR LOCATION.
RX   PubMed=11598301; DOI=10.1126/science.1062030;
RA   Maira S.-M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M.,
RA   Hemmings B.A.;
RT   "Carboxyl-terminal modulator protein (CTMP), a negative regulator of
RT   PKB/Akt and v-Akt at the plasma membrane.";
RL   Science 294:374-380(2001).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF TBC1D4.
RX   PubMed=11994271; DOI=10.1074/jbc.C200198200;
RA   Kane S., Sano H., Liu S.C.H., Asara J.M., Lane W.S., Garner C.C.,
RA   Lienhard G.E.;
RT   "A method to identify serine kinase substrates. Akt phosphorylates a
RT   novel adipocyte protein with a Rab GTPase-activating protein (GAP)
RT   domain.";
RL   J. Biol. Chem. 277:22115-22118(2002).
RN   [21]
RP   INTERACTION WITH CDKN1B, AND FUNCTION.
RX   PubMed=12042314; DOI=10.1074/jbc.M203668200;
RA   Fujita N., Sato S., Katayama K., Tsuruo T.;
RT   "Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3
RT   and cytoplasmic localization.";
RL   J. Biol. Chem. 277:28706-28713(2002).
RN   [22]
RP   PHOSPHORYLATION AT TYR-474, AND MUTAGENESIS OF TYR-474.
RX   PubMed=12149249; DOI=10.1074/jbc.M203387200;
RA   Conus N.M., Hannan K.M., Cristiano B.E., Hemmings B.A., Pearson R.B.;
RT   "Direct identification of tyrosine 474 as a regulatory phosphorylation
RT   site for the Akt protein kinase.";
RL   J. Biol. Chem. 277:38021-38028(2002).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF TSC2.
RX   PubMed=12150915; DOI=10.1016/S1097-2765(02)00568-3;
RA   Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C.;
RT   "Identification of the tuberous sclerosis complex-2 tumor suppressor
RT   gene product tuberin as a target of the phosphoinositide 3-kinase/akt
RT   pathway.";
RL   Mol. Cell 10:151-162(2002).
RN   [24]
RP   INTERACTION WITH TCL1A.
RX   PubMed=11839817; DOI=10.1128/MCB.22.5.1513-1525.2002;
RA   Kuenstle G., Laine J., Pierron G., Kagami S., Nakajima H., Hoh F.,
RA   Roumestand C., Stern M.H., Noguchi M.;
RT   "Identification of Akt association and oligomerization domains of the
RT   Akt kinase coactivator TCL1.";
RL   Mol. Cell. Biol. 22:1513-1525(2002).
RN   [25]
RP   INTERACTION WITH CDKN1B, FUNCTION, AND MUTAGENESIS OF THR-308 AND
RP   SER-473.
RX   PubMed=12244301; DOI=10.1038/nm759;
RA   Shin I., Yakes F.M., Rojo F., Shin N.-Y., Bakin A.V., Baselga J.,
RA   Arteaga C.L.;
RT   "PKB/Akt mediates cell-cycle progression by phosphorylation of
RT   p27(Kip1) at threonine 157 and modulation of its cellular
RT   localization.";
RL   Nat. Med. 8:1145-1152(2002).
RN   [26]
RP   FUNCTION IN PARTICIPATION IN KIT SIGNALING.
RX   PubMed=12878163; DOI=10.1016/S0014-4827(03)00206-4;
RA   Lennartsson J., Wernstedt C., Engstrom U., Hellman U., Ronnstrand L.;
RT   "Identification of Tyr900 in the kinase domain of c-Kit as a Src-
RT   dependent phosphorylation site mediating interaction with c-Crk.";
RL   Exp. Cell Res. 288:110-118(2003).
RN   [27]
RP   INTERACTION WITH AGAP2, AND PHOSPHORYLATION AT SER-473.
RX   PubMed=14761976; DOI=10.1074/jbc.M312175200;
RA   Ahn J.-Y., Rong R., Kroll T.G., Van Meir E.G., Snyder S.H., Ye K.;
RT   "PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt
RT   activity and mediates cellular invasion.";
RL   J. Biol. Chem. 279:16441-16451(2004).
RN   [28]
RP   PHOSPHORYLATION AT SER-473.
RX   PubMed=15047712; DOI=10.1074/jbc.M314192200;
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RT   "LGI1, a putative tumor metastasis suppressor gene, controls in vitro
RT   invasiveness and expression of matrix metalloproteinases in glioma
RT   cells through the ERK1/2 pathway.";
RL   J. Biol. Chem. 279:23151-23157(2004).
RN   [29]
RP   ERRATUM.
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RL   J. Biol. Chem. 282:2752-2752(2007).
RN   [30]
RP   INTERACTION WITH AKTIP.
RX   PubMed=14749367; DOI=10.1128/MCB.24.4.1493-1504.2004;
RA   Remy I., Michnick S.W.;
RT   "Regulation of apoptosis by the Ft1 protein, a new modulator of
RT   protein kinase B/Akt.";
RL   Mol. Cell. Biol. 24:1493-1504(2004).
RN   [31]
RP   INTERACTION WITH AGAP2.
RX   PubMed=15118108; DOI=10.1073/pnas.0400921101;
RA   Ahn J.-Y., Hu Y., Kroll T.G., Allard P., Ye K.;
RT   "PIKE-A is amplified in human cancers and prevents apoptosis by up-
RT   regulating Akt.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:6993-6998(2004).
RN   [32]
RP   PHOSPHORYLATION AT SER-473 IN RESPONSE TO FLT3 SIGNALING.
RX   PubMed=16266983; DOI=10.1158/0008-5472.CAN-05-0422;
RA   Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B.,
RA   Schwable J., Buerger H., Muller-Tidow C., Choudhary C., McMahon M.,
RA   Berdel W.E., Serve H.;
RT   "Constitutive activation of Akt by Flt3 internal tandem duplications
RT   is necessary for increased survival, proliferation, and myeloid
RT   transformation.";
RL   Cancer Res. 65:9643-9650(2005).
RN   [33]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH CCDC88A.
RX   PubMed=16139227; DOI=10.1016/j.devcel.2005.08.001;
RA   Enomoto A., Murakami H., Asai N., Morone N., Watanabe T., Kawai K.,
RA   Murakumo Y., Usukura J., Kaibuchi K., Takahashi M.;
RT   "Akt/PKB regulates actin organization and cell motility via
RT   Girdin/APE.";
RL   Dev. Cell 9:389-402(2005).
RN   [34]
RP   PHOSPHORYLATION AT THR-308, AND PHOSPHORYLATION AT SER-473 BY MTOR.
RX   PubMed=15718470; DOI=10.1126/science.1106148;
RA   Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.;
RT   "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR
RT   complex.";
RL   Science 307:1098-1101(2005).
RN   [35]
RP   PHOSPHORYLATION AT SER-473.
RX   PubMed=17013611; DOI=10.1007/s00401-006-0128-y;
RA   Schick V., Majores M., Engels G., Spitoni S., Koch A., Elger C.E.,
RA   Simon M., Knobbe C., Bluemcke I., Becker A.J.;
RT   "Activation of Akt independent of PTEN and CTMP tumor-suppressor gene
RT   mutations in epilepsy-associated Taylor-type focal cortical
RT   dysplasias.";
RL   Acta Neuropathol. 112:715-725(2006).
RN   [36]
RP   INTERACTION WITH WDFY2, AND SUBCELLULAR LOCATION.
RX   PubMed=16792529; DOI=10.1042/BJ20060511;
RA   Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M.,
RA   Bosse M., Zimmermann S., Frey A.D., Caelers A., Bachmann A.S.,
RA   Moelling K.;
RT   "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda.";
RL   Biochem. J. 399:9-20(2006).
RN   [37]
RP   FUNCTION, AND INTERACTION WITH RARA.
RX   PubMed=16417524; DOI=10.1042/BJ20051794;
RA   Srinivas H., Xia D., Moore N.L., Uray I.P., Kim H., Ma L.,
RA   Weigel N.L., Brown P.H., Kurie J.M.;
RT   "Akt phosphorylates and suppresses the transactivation of retinoic
RT   acid receptor alpha.";
RL   Biochem. J. 395:653-662(2006).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [39]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16540465; DOI=10.1074/jbc.M601384200;
RA   Zhang X., Zhang S., Yamane H., Wahl R., Ali A., Lofgren J.A.,
RA   Kendall R.L.;
RT   "Kinetic mechanism of AKT/PKB enzyme family.";
RL   J. Biol. Chem. 281:13949-13956(2006).
RN   [40]
RP   FUNCTION IN PHOSPHORYLATION OF CDKN1A.
RX   PubMed=16982699; DOI=10.1128/MCB.00201-06;
RA   Heron-Milhavet L., Franckhauser C., Rana V., Berthenet C., Fisher D.,
RA   Hemmings B.A., Fernandez A., Lamb N.J.;
RT   "Only Akt1 is required for proliferation, while Akt2 promotes cell
RT   cycle exit through p21 binding.";
RL   Mol. Cell. Biol. 26:8267-8280(2006).
RN   [41]
RP   INTERACTION WITH STK4/MST1, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=17932490; DOI=10.1038/sj.emboj.7601872;
RA   Cinar B., Fang P.K., Lutchman M., Di Vizio D., Adam R.M., Pavlova N.,
RA   Rubin M.A., Yelick P.C., Freeman M.R.;
RT   "The pro-apoptotic kinase Mst1 and its caspase cleavage products are
RT   direct inhibitors of Akt1.";
RL   EMBO J. 26:4523-4534(2007).
RN   [42]
RP   FUNCTION, AND INTERACTION WITH STK4/MST1.
RX   PubMed=17726016; DOI=10.1074/jbc.M704542200;
RA   Jang S.W., Yang S.J., Srinivasan S., Ye K.;
RT   "Akt phosphorylates MstI and prevents its proteolytic activation,
RT   blocking FOXO3 phosphorylation and nuclear translocation.";
RL   J. Biol. Chem. 282:30836-30844(2007).
RN   [43]
RP   FUNCTION IN PHOSPHORYLATION OF PROHIBITIN.
RX   PubMed=18507042;
RA   Han E.K., Mcgonigal T., Butler C., Giranda V.L., Luo Y.;
RT   "Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin
RT   is an Akt substrate both in vitro and in cells.";
RL   Anticancer Res. 28:957-963(2008).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-126 AND
RP   SER-129, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [45]
RP   UBIQUITINATION BY TTC3.
RX   PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007;
RA   Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J.,
RA   Hirata N., Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C.,
RA   Hatakeyama S., Obata T., Noguchi M.;
RT   "The E3 ligase TTC3 facilitates ubiquitination and degradation of
RT   phosphorylated Akt.";
RL   Dev. Cell 17:800-810(2009).
RN   [46]
RP   FUNCTION IN PHOSPHORYLATION OF SRPK2, AND INTERACTION WITH SRPK2.
RX   PubMed=19592491; DOI=10.1074/jbc.M109.026237;
RA   Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.;
RT   "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell
RT   cycle and cell death in neurons.";
RL   J. Biol. Chem. 284:24512-24525(2009).
RN   [47]
RP   FUNCTION.
RX   PubMed=19934221; DOI=10.1242/jcs.053728;
RA   Bristow J.M., Sellers M.H., Majumdar D., Anderson B., Hu L.,
RA   Webb D.J.;
RT   "The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin
RT   dynamics and thereby regulate cell migration.";
RL   J. Cell Sci. 122:4535-4546(2009).
RN   [48]
RP   UBIQUITINATION, INTERACTION WITH TRAF6, MUTAGENESIS OF LYS-8 AND
RP   LYS-14, AND CHARACTERIZATION OF VARIANT BREAST CANCER LYS-17.
RX   PubMed=19713527; DOI=10.1126/science.1175065;
RA   Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B.,
RA   Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.;
RT   "The E3 ligase TRAF6 regulates Akt ubiquitination and activation.";
RL   Science 325:1134-1138(2009).
RN   [49]
RP   FUNCTION, AND INTERACTION WITH STK3/MST2.
RX   PubMed=20086174; DOI=10.1158/0008-5472.CAN-09-3147;
RA   Romano D., Matallanas D., Weitsman G., Preisinger C., Ng T., Kolch W.;
RT   "Proapoptotic kinase MST2 coordinates signaling crosstalk between
RT   RASSF1A, Raf-1, and Akt.";
RL   Cancer Res. 70:1195-1203(2010).
RN   [50]
RP   FUNCTION.
RX   PubMed=19940129; DOI=10.1074/jbc.M109.059675;
RA   Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S.,
RA   Coppola D., Cheng J.Q.;
RT   "Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic
RT   signaling through phosphorylation of threonine 120.";
RL   J. Biol. Chem. 285:3815-3824(2010).
RN   [51]
RP   FUNCTION, AND INTERACTION WITH CLK2.
RX   PubMed=20682768; DOI=10.1074/jbc.M110.122044;
RA   Nam S.Y., Seo H.H., Park H.S., An S., Kim J.Y., Yang K.H., Kim C.S.,
RA   Jeong M., Jin Y.W.;
RT   "Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT
RT   controls cell survival after ionizing radiation.";
RL   J. Biol. Chem. 285:31157-31163(2010).
RN   [52]
RP   FUNCTION IN PHOSPHORYLATION OF PALLD.
RX   PubMed=20471940; DOI=10.1016/j.molcel.2010.02.031;
RA   Chin Y.R., Toker A.;
RT   "The actin-bundling protein palladin is an Akt1-specific substrate
RT   that regulates breast cancer cell migration.";
RL   Mol. Cell 38:333-344(2010).
RN   [53]
RP   FUNCTION, AND INTERACTION WITH STK3/MST2.
RX   PubMed=20231902; DOI=10.1371/journal.pone.0009616;
RA   Kim D., Shu S., Coppola M.D., Kaneko S., Yuan Z.Q., Cheng J.Q.;
RT   "Regulation of proapoptotic mammalian ste20-like kinase MST2 by the
RT   IGF1-Akt pathway.";
RL   PLoS ONE 5:E9616-E9616(2010).
RN   [54]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-176; THR-308
RP   AND SER-473, MUTAGENESIS OF TYR-176, INTERACTION WITH TNK2, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=20333297; DOI=10.1371/journal.pone.0009646;
RA   Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W.,
RA   Lopez A.S., Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S.,
RA   Cheng J.Q., Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.;
RT   "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its
RT   activation.";
RL   PLoS ONE 5:E9646-E9646(2010).
RN   [55]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [56]
RP   INTERACTION WITH TRIM13, AND UBIQUITINATION.
RX   PubMed=21333377; DOI=10.1016/j.ejcb.2010.12.001;
RA   Joo H.M., Kim J.Y., Jeong J.B., Seong K.M., Nam S.Y., Yang K.H.,
RA   Kim C.S., Kim H.S., Jeong M., An S., Jin Y.W.;
RT   "Ret finger protein 2 enhances ionizing radiation-induced apoptosis
RT   via degradation of AKT and MDM2.";
RL   Eur. J. Cell Biol. 90:420-431(2011).
RN   [57]
RP   INTERACTION WITH PPP2R5B, AND DEPHOSPHORYLATION.
RX   PubMed=21329884; DOI=10.1016/j.molcel.2011.02.007;
RA   Rodgers J.T., Vogel R.O., Puigserver P.;
RT   "Clk2 and B56-beta mediate insulin-regulated assembly of the PP2A
RT   phosphatase holoenzyme complex on Akt.";
RL   Mol. Cell 41:471-479(2011).
RN   [58]
RP   INTERACTION WITH FAM168A.
RX   PubMed=23251525; DOI=10.1371/journal.pone.0051413;
RA   Peng B., Gu Y., Xiong Y., Zheng G., He Z.;
RT   "Microarray-assisted pathway analysis identifies MT1X & NFkappaB as
RT   mediators of TCRP1-associated resistance to cisplatin in oral squamous
RT   cell carcinoma.";
RL   PLoS ONE 7:E51413-E51413(2012).
RN   [59]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [60]
RP   INTERACTION WITH FAM83B.
RX   PubMed=23676467;
RA   Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A.,
RA   Jackson M.W.;
RT   "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates
RT   to promote epithelial cell transformation and resistance to targeted
RT   therapies.";
RL   Oncotarget 4:729-738(2013).
RN   [61]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [62]
RP   REVIEW ON FUNCTION.
RX   PubMed=11882383; DOI=10.1016/S0898-6568(01)00271-6;
RA   Nicholson K.M., Anderson N.G.;
RT   "The protein kinase B/Akt signalling pathway in human malignancy.";
RL   Cell. Signal. 14:381-395(2002).
RN   [63]
RP   PHOSPHORYLATION AT SER-473.
RX   PubMed=20978158; DOI=10.1158/1535-7163.MCT-10-0730;
RA   Kunoh T., Noda T., Koseki K., Sekigawa M., Takagi M., Shin-ya K.,
RA   Goshima N., Iemura S., Natsume T., Wada S., Mukai Y., Ohta S.,
RA   Sasaki R., Mizukami T.;
RT   "A novel human dynactin-associated protein, dynAP, promotes activation
RT   of Akt, and ergosterol-related compounds induce dynAP-dependent
RT   apoptosis of human cancer cells.";
RL   Mol. Cancer Ther. 9:2934-2942(2010).
RN   [64]
RP   REVIEW ON FUNCTION.
RX   PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004;
RA   Hers I., Vincent E.E., Tavare J.M.;
RT   "Akt signalling in health and disease.";
RL   Cell. Signal. 23:1515-1527(2011).
RN   [65]
RP   REVIEW ON FUNCTION.
RX   PubMed=21432781; DOI=10.14670/HH-26.651;
RA   Heron-Milhavet L., Khouya N., Fernandez A., Lamb N.J.;
RT   "Akt1 and Akt2: differentiating the aktion.";
RL   Histol. Histopathol. 26:651-662(2011).
RN   [66]
RP   PHOSPHORYLATION AT THR-308 AND SER-473.
RX   PubMed=21464307; DOI=10.1073/pnas.1016132108;
RA   Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y.,
RA   Guan K.L.;
RT   "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by
RT   direct phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011).
RN   [67]
RP   INTERACTION WITH SIRT1, ACETYLATION AT LYS-14 AND LYS-20,
RP   DEACETYLATION AT LYS-14 AND LYS-20, AND MUTAGENESIS OF LYS-14; GLU-17
RP   AND LYS-20.
RX   PubMed=21775285; DOI=10.1126/scisignal.2001465;
RA   Sundaresan N.R., Pillai V.B., Wolfgeher D., Samant S., Vasudevan P.,
RA   Parekh V., Raghuraman H., Cunningham J.M., Gupta M., Gupta M.P.;
RT   "The deacetylase SIRT1 promotes membrane localization and activation
RT   of Akt and PDK1 during tumorigenesis and cardiac hypertrophy.";
RL   Sci. Signal. 4:RA46-RA46(2011).
RN   [68]
RP   UBIQUITINATION AT LYS-284.
RX   PubMed=22410793; DOI=10.1038/cr.2012.38;
RA   Bae S., Kim S.Y., Jung J.H., Yoon Y., Cha H.J., Lee H., Kim K.,
RA   Kim J., An I.S., Kim J., Um H.D., Park I.C., Lee S.J., Nam S.Y.,
RA   Jin Y.W., Lee J.H., An S.;
RT   "Akt is negatively regulated by the MULAN E3 ligase.";
RL   Cell Res. 22:873-885(2012).
RN   [69]
RP   GLYCOSYLATION AT SER-126; SER-129; THR-305 AND THR-312, SUBCELLULAR
RP   LOCATION, INTERACTION WITH PDPK1, AND MUTAGENESIS OF THR-305 AND
RP   THR-312.
RX   PubMed=22629392; DOI=10.1371/journal.pone.0037427;
RA   Wang S., Huang X., Sun D., Xin X., Pan Q., Peng S., Liang Z., Luo C.,
RA   Yang Y., Jiang H., Huang M., Chai W., Ding J., Geng M.;
RT   "Extensive crosstalk between O-GlcNAcylation and phosphorylation
RT   regulates Akt signaling.";
RL   PLoS ONE 7:E37427-E37427(2012).
RN   [70]
RP   PHOSPHORYLATION AT SER-473, AND DEPHOSPHORYLATION BY CPPED1.
RX   PubMed=23799035; DOI=10.1371/journal.pone.0065679;
RA   Zhuo D.X., Zhang X.W., Jin B., Zhang Z., Xie B.S., Wu C.L., Gong K.,
RA   Mao Z.B.;
RT   "CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell
RT   apoptosis, and suppresses tumor growth of bladder cancer by directly
RT   dephosphorylating Akt at Ser473 site.";
RL   PLoS ONE 8:E65679-E65679(2013).
RN   [71]
RP   FUNCTION.
RX   PubMed=23431171; DOI=10.1073/pnas.1300490110;
RA   Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I.,
RA   Prives C.;
RT   "MOZ increases p53 acetylation and premature senescence through its
RT   complex formation with PML.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013).
RN   [72]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-448 AND THR-450, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [73]
RP   INTERACTION WITH KIF14.
RX   PubMed=24784001; DOI=10.1016/j.neo.2014.03.008;
RA   Singel S.M., Cornelius C., Zaganjor E., Batten K., Sarode V.R.,
RA   Buckley D.L., Peng Y., John G.B., Li H.C., Sadeghi N., Wright W.E.,
RA   Lum L., Corson T.W., Shay J.W.;
RT   "KIF14 promotes AKT phosphorylation and contributes to chemoresistance
RT   in triple-negative breast cancer.";
RL   Neoplasia 16:247-256(2014).
RN   [74]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-123, INTERACTION WITH
RP   PTDINS(3,4,5)P3 AND PTDINS(3,4)P2, AND MUTAGENESIS OF LYS-14; ARG-25
RP   AND ARG-86.
RX   PubMed=12176338; DOI=10.1016/S0960-9822(02)00972-7;
RA   Thomas C.C., Deak M., Alessi D.R., van Aalten D.M.;
RT   "High-resolution structure of the pleckstrin homology domain of
RT   protein kinase b/akt bound to phosphatidylinositol (3,4,5)-
RT   trisphosphate.";
RL   Curr. Biol. 12:1256-1262(2002).
RN   [75]
RP   X-RAY CRYSTALLOGRAPHY (0.98 ANGSTROMS) OF 1-121, AND INTERACTION WITH
RP   PTDINS(1,3,4,5)P4.
RX   PubMed=12964941; DOI=10.1042/BJ20031229;
RA   Milburn C.C., Deak M., Kelly S.M., Price N.C., Alessi D.R.,
RA   Van Aalten D.M.;
RT   "Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin
RT   homology domain of protein kinase B induces a conformational change.";
RL   Biochem. J. 375:531-538(2003).
RN   [76]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT
RP   THR-308, AND ENZYME REGULATION.
RX   PubMed=18456494; DOI=10.1016/j.bmcl.2008.04.034;
RA   Lippa B., Pan G., Corbett M., Li C., Kauffman G.S., Pandit J.,
RA   Robinson S., Wei L., Kozina E., Marr E.S., Borzillo G., Knauth E.,
RA   Barbacci-Tobin E.G., Vincent P., Troutman M., Baker D., Rajamohan F.,
RA   Kakar S., Clark T., Morris J.;
RT   "Synthesis and structure based optimization of novel Akt inhibitors.";
RL   Bioorg. Med. Chem. Lett. 18:3359-3363(2008).
RN   [77]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 144-480, AND ENZYME
RP   REGULATION.
RX   PubMed=20810279; DOI=10.1016/j.bmcl.2010.08.053;
RA   Blake J.F., Kallan N.C., Xiao D., Xu R., Bencsik J.R., Skelton N.J.,
RA   Spencer K.L., Mitchell I.S., Woessner R.D., Gloor S.L., Risom T.,
RA   Gross S.D., Martinson M., Morales T.H., Vigers G.P., Brandhuber B.J.;
RT   "Discovery of pyrrolopyrimidine inhibitors of Akt.";
RL   Bioorg. Med. Chem. Lett. 20:5607-5612(2010).
RN   [78]
RP   X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT
RP   THR-308, AND ENZYME REGULATION.
RX   PubMed=20481595; DOI=10.1021/jm1003842;
RA   Freeman-Cook K.D., Autry C., Borzillo G., Gordon D.,
RA   Barbacci-Tobin E., Bernardo V., Briere D., Clark T., Corbett M.,
RA   Jakubczak J., Kakar S., Knauth E., Lippa B., Luzzio M.J., Mansour M.,
RA   Martinelli G., Marx M., Nelson K., Pandit J., Rajamohan F.,
RA   Robinson S., Subramanyam C., Wei L., Wythes M., Morris J.;
RT   "Design of selective, ATP-competitive inhibitors of Akt.";
RL   J. Med. Chem. 53:4615-4622(2010).
RN   [79]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2-443, AND DISULFIDE BOND.
RX   PubMed=20886116; DOI=10.1371/journal.pone.0012913;
RA   Wu W.I., Voegtli W.C., Sturgis H.L., Dizon F.P., Vigers G.P.,
RA   Brandhuber B.J.;
RT   "Crystal structure of human AKT1 with an allosteric inhibitor reveals
RT   a new mode of kinase inhibition.";
RL   PLoS ONE 5:E12913-E12913(2010).
RN   [80]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 144-480, AND ENZYME
RP   REGULATION.
RX   PubMed=21392984; DOI=10.1016/j.bmcl.2011.02.073;
RA   Kallan N.C., Spencer K.L., Blake J.F., Xu R., Heizer J., Bencsik J.R.,
RA   Mitchell I.S., Gloor S.L., Martinson M., Risom T., Gross S.D.,
RA   Morales T.H., Wu W.I., Vigers G.P., Brandhuber B.J., Skelton N.J.;
RT   "Discovery and SAR of spirochromane Akt inhibitors.";
RL   Bioorg. Med. Chem. Lett. 21:2410-2414(2011).
RN   [81]
RP   VARIANT BREAST CANCER LYS-17, AND CHARACTERIZATION OF VARIANT BREAST
RP   CANCER LYS-17.
RX   PubMed=17611497; DOI=10.1038/nature05933;
RA   Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L.,
RA   Robbins C.M., Hostetter G., Boguslawski S., Moses T.Y., Savage S.,
RA   Uhlik M., Lin A., Du J., Qian Y.-W., Zeckner D.J., Tucker-Kellogg G.,
RA   Touchman J., Patel K., Mousses S., Bittner M., Schevitz R.,
RA   Lai M.-H.T., Blanchard K.L., Thomas J.E.;
RT   "A transforming mutation in the pleckstrin homology domain of AKT1 in
RT   cancer.";
RL   Nature 448:439-444(2007).
RN   [82]
RP   CHARACTERIZATION OF VARIANT PROTEUSS LYS-17.
RX   PubMed=18954143; DOI=10.1021/bi801683k;
RA   Landgraf K.E., Pilling C., Falke J.J.;
RT   "Molecular mechanism of an oncogenic mutation that alters membrane
RT   targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH
RT   domain.";
RL   Biochemistry 47:12260-12269(2008).
RN   [83]
RP   VARIANT PROTEUSS LYS-17.
RX   PubMed=21793738; DOI=10.1056/NEJMoa1104017;
RA   Lindhurst M.J., Sapp J.C., Teer J.K., Johnston J.J., Finn E.M.,
RA   Peters K., Turner J., Cannons J.L., Bick D., Blakemore L.,
RA   Blumhorst C., Brockmann K., Calder P., Cherman N., Deardorff M.A.,
RA   Everman D.B., Golas G., Greenstein R.M., Kato B.M.,
RA   Keppler-Noreuil K.M., Kuznetsov S.A., Miyamoto R.T., Newman K., Ng D.,
RA   O'Brien K., Rothenberg S., Schwartzentruber D.J., Singhal V.,
RA   Tirabosco R., Upton J., Wientroub S., Zackai E.H., Hoag K.,
RA   Whitewood-Neal T., Robey P.G., Schwartzberg P.L., Darling T.N.,
RA   Tosi L.L., Mullikin J.C., Biesecker L.G.;
RT   "A mosaic activating mutation in AKT1 associated with the Proteus
RT   syndrome.";
RL   N. Engl. J. Med. 365:611-619(2011).
RN   [84]
RP   VARIANTS CWS6 CYS-25 AND PRO-435.
RX   PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021;
RA   Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L.,
RA   Eng C.;
RT   "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like
RT   syndromes.";
RL   Am. J. Hum. Genet. 92:76-80(2013).
CC   -!- FUNCTION: AKT1 is one of 3 closely related serine/threonine-
CC       protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and
CC       which regulate many processes including metabolism, proliferation,
CC       cell survival, growth and angiogenesis. This is mediated through
CC       serine and/or threonine phosphorylation of a range of downstream
CC       substrates. Over 100 substrate candidates have been reported so
CC       far, but for most of them, no isoform specificity has been
CC       reported. AKT is responsible of the regulation of glucose uptake
CC       by mediating insulin-induced translocation of the SLC2A4/GLUT4
CC       glucose transporter to the cell surface. Phosphorylation of PTPN1
CC       at 'Ser-50' negatively modulates its phosphatase activity
CC       preventing dephosphorylation of the insulin receptor and the
CC       attenuation of insulin signaling. Phosphorylation of TBC1D4
CC       triggers the binding of this effector to inhibitory 14-3-3
CC       proteins, which is required for insulin-stimulated glucose
CC       transport. AKT regulates also the storage of glucose in the form
CC       of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at
CC       'Ser-9', resulting in inhibition of its kinase activity.
CC       Phosphorylation of GSK3 isoforms by AKT is also thought to be one
CC       mechanism by which cell proliferation is driven. AKT regulates
CC       also cell survival via the phosphorylation of MAP3K5 (apoptosis
CC       signal-related kinase). Phosphorylation of 'Ser-83' decreases
CC       MAP3K5 kinase activity stimulated by oxidative stress and thereby
CC       prevents apoptosis. AKT mediates insulin-stimulated protein
CC       synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462',
CC       thereby activating mTORC1 signaling and leading to both
CC       phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is
CC       involved in the phosphorylation of members of the FOXO factors
CC       (Forkhead family of transcription factors), leading to binding of
CC       14-3-3 proteins and cytoplasmic localization. In particular, FOXO1
CC       is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and
CC       FOXO4 are phosphorylated on equivalent sites. AKT has an important
CC       role in the regulation of NF-kappa-B-dependent gene transcription
CC       and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-
CC       response element binding protein). The phosphorylation of CREB1
CC       induces the binding of accessory proteins that are necessary for
CC       the transcription of pro-survival genes such as BCL2 and MCL1. AKT
CC       phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby
CC       potentially regulating ACLY activity and fatty acid synthesis.
CC       Activates the 3B isoform of cyclic nucleotide phosphodiesterase
CC       (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced
CC       cyclic AMP levels and inhibition of lipolysis. Phosphorylates
CC       PIKFYVE on 'Ser-318', which results in increased PI(3)P-5
CC       activity. The Rho GTPase-activating protein DLC1 is another
CC       substrate and its phosphorylation is implicated in the regulation
CC       cell proliferation and cell growth. AKT plays a role as key
CC       modulator of the AKT-mTOR signaling pathway controlling the tempo
CC       of the process of newborn neurons integration during adult
CC       neurogenesis, including correct neuron positioning, dendritic
CC       development and synapse formation. Signals downstream of
CC       phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of
CC       various growth factors such as platelet-derived growth factor
CC       (PDGF), epidermal growth factor (EGF), insulin and insulin-like
CC       growth factor I (IGF-I). AKT mediates the antiapoptotic effects of
CC       IGF-I. Essential for the SPATA13-mediated regulation of cell
CC       migration and adhesion assembly and disassembly. May be involved
CC       in the regulation of the placental development. Phosphorylates
CC       STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its:
CC       kinase activity, nuclear translocation, autophosphorylation and
CC       ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-
CC       117' and 'Thr-384' leading to inhibition of its: cleavage, kinase
CC       activity, autophosphorylation at Thr-180, binding to RASSF1 and
CC       nuclear translocation. Phosphorylates SRPK2 and enhances its
CC       kinase activity towards SRSF2 and ACIN1 and promotes its nuclear
CC       translocation. Phosphorylates RAF1 at 'Ser-259' and negatively
CC       regulates its activity. Phosphorylation of BAD stimulates its pro-
CC       apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and this
CC       phosphorylation inhibits the interaction of KAT6A with PML and
CC       negatively regulates its acetylation activity towards p53/TP53.
CC   -!- FUNCTION: AKT1-specific substrates have been recently identified,
CC       including palladin (PALLD), which phosphorylation modulates
CC       cytoskeletal organization and cell motility; prohibitin (PHB),
CC       playing an important role in cell metabolism and proliferation;
CC       and CDKN1A, for which phosphorylation at 'Thr-145' induces its
CC       release from CDK2 and cytoplasmic relocalization. These recent
CC       findings indicate that the AKT1 isoform has a more specific role
CC       in cell motility and proliferation. Phosphorylates CLK2 thereby
CC       controlling cell survival to ionizing radiation.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748,
CC       ECO:0000269|PubMed:1851997}.
CC   -!- ENZYME REGULATION: Three specific sites, one in the kinase domain
CC       (Thr-308) and the two other ones in the C-terminal regulatory
CC       region (Ser-473 and Tyr-474), need to be phosphorylated for its
CC       full activation. Inhibited by pyrrolopyrimidine inhibitors like
CC       aniline triazole and spiroindoline. {ECO:0000269|PubMed:18456494,
CC       ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20810279,
CC       ECO:0000269|PubMed:21392984, ECO:0000269|PubMed:9512493,
CC       ECO:0000269|PubMed:9736715}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=52.8 uM for ATP (for purified and in vitro activated AKT1)
CC         {ECO:0000269|PubMed:16540465};
CC         KM=0.5 uM for peptide substrate (for purified and in vitro
CC         activated AKT1) {ECO:0000269|PubMed:16540465};
CC         KM=143.3 uM for ATP (for recombinant myristoylated AKT1
CC         expressed and immunoprecipitated from Rat-1 cells)
CC         {ECO:0000269|PubMed:16540465};
CC         KM=2.9 uM for peptide substrate (for recombinant myristoylated
CC         AKT1 expressed and immunoprecipitated from Rat-1 cells)
CC         {ECO:0000269|PubMed:16540465};
CC   -!- SUBUNIT: Interacts with BTBD10 (By similarity). Interacts with
CC       KCTD20 (By similarity). Interacts (via the C-terminus) with
CC       CCDC88A (via its C-terminus). Interacts with GRB10; the
CC       interaction leads to GRB10 phosphorylation thus promoting YWHAE-
CC       binding (By similarity). Interacts with AGAP2 (isoform 2/PIKE-A);
CC       the interaction occurs in the presence of guanine nucleotides.
CC       Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1A
CC       AND TCL1B. Interacts with CDKN1B; the interaction phosphorylates
CC       CDKN1B promoting 14-3-3 binding and cell-cycle progression.
CC       Interacts with MAP3K5 and TRAF6. Interacts with BAD, PPP2R5B, STK3
CC       and STK4. Interacts (via PH domain) with SIRT1. Interacts with
CC       SRPK2 in a phosphorylation-dependent manner. Interacts with RAF1.
CC       Interacts with TRIM13; the interaction ubiquitinates AKT1 leading
CC       to its proteasomal degradation. Interacts with TNK2 and CLK2.
CC       Interacts (via the C-terminus) with THEM4 (via its C-terminus).
CC       Interacts with and phosphorylated by PDPK1. Interacts with PA2G4
CC       (By similarity). Interacts with KIF14; the interaction is detected
CC       in the plasma membrane upon INS stimulation and promotes AKT1
CC       phosphorylation (PubMed:24784001). Interacts with FAM83B;
CC       activates the PI3K/AKT signaling cascade (PubMed:23676467).
CC       Interacts with WDFY2 (via WD repeats 1-3) (PubMed:16792529). Forms
CC       a complex with WDFY2 and FOXO1 (By similarity). Interacts with
CC       FAM168A (PubMed:23251525). {ECO:0000250|UniProtKB:P31750,
CC       ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10576742,
CC       ECO:0000269|PubMed:10716693, ECO:0000269|PubMed:10926925,
CC       ECO:0000269|PubMed:10983986, ECO:0000269|PubMed:11154276,
CC       ECO:0000269|PubMed:11598301, ECO:0000269|PubMed:11839817,
CC       ECO:0000269|PubMed:12042314, ECO:0000269|PubMed:12176338,
CC       ECO:0000269|PubMed:12244301, ECO:0000269|PubMed:12964941,
CC       ECO:0000269|PubMed:14749367, ECO:0000269|PubMed:14761976,
CC       ECO:0000269|PubMed:15118108, ECO:0000269|PubMed:16139227,
CC       ECO:0000269|PubMed:16417524, ECO:0000269|PubMed:16792529,
CC       ECO:0000269|PubMed:17726016, ECO:0000269|PubMed:17932490,
CC       ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:19713527,
CC       ECO:0000269|PubMed:20086174, ECO:0000269|PubMed:20231902,
CC       ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768,
CC       ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377,
CC       ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392,
CC       ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23676467,
CC       ECO:0000269|PubMed:24784001}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-296087, EBI-296087;
CC       Q9UKG1:APPL1; NbExp=2; IntAct=EBI-296087, EBI-741243;
CC       P29067:Arrb2 (xeno); NbExp=2; IntAct=EBI-296087, EBI-1636616;
CC       Q8IXJ9:ASXL1; NbExp=2; IntAct=EBI-296087, EBI-1646500;
CC       O95999:BCL10; NbExp=5; IntAct=EBI-296087, EBI-958922;
CC       Q16543:CDC37; NbExp=2; IntAct=EBI-296087, EBI-295634;
CC       Q92793:CREBBP; NbExp=3; IntAct=EBI-296087, EBI-81215;
CC       Q1W6H9:FAM110C; NbExp=2; IntAct=EBI-296087, EBI-3942563;
CC       Q9BZQ8:FAM129A; NbExp=2; IntAct=EBI-296087, EBI-6916466;
CC       P49841:GSK3B; NbExp=3; IntAct=EBI-296087, EBI-373586;
CC       P11021:HSPA5; NbExp=2; IntAct=EBI-296087, EBI-354921;
CC       Q5S007:LRRK2; NbExp=6; IntAct=EBI-296087, EBI-5323863;
CC       Q99683:MAP3K5; NbExp=2; IntAct=EBI-296087, EBI-476263;
CC       Q16539:MAPK14; NbExp=2; IntAct=EBI-296087, EBI-73946;
CC       Q00987:MDM2; NbExp=4; IntAct=EBI-296087, EBI-389668;
CC       P42345:MTOR; NbExp=2; IntAct=EBI-296087, EBI-359260;
CC       P29474:NOS3; NbExp=2; IntAct=EBI-296087, EBI-1391623;
CC       P04150:NR3C1; NbExp=5; IntAct=EBI-296087, EBI-493507;
CC       Q15118-1:PDK1; NbExp=2; IntAct=EBI-12562306, EBI-12562315;
CC       O15530:PDPK1; NbExp=3; IntAct=EBI-296087, EBI-717097;
CC       Q96S96:PEBP4; NbExp=2; IntAct=EBI-296087, EBI-8563667;
CC       P19174:PLCG1; NbExp=9; IntAct=EBI-296087, EBI-79387;
CC       O60437:PPL; NbExp=2; IntAct=EBI-296087, EBI-368321;
CC       P62136:PPP1CA; NbExp=4; IntAct=EBI-296087, EBI-357253;
CC       P67775:PPP2CA; NbExp=4; IntAct=EBI-296087, EBI-712311;
CC       P30153:PPP2R1A; NbExp=2; IntAct=EBI-296087, EBI-302388;
CC       Q05513:PRKCZ; NbExp=2; IntAct=EBI-296087, EBI-295351;
CC       P04049:RAF1; NbExp=2; IntAct=EBI-296087, EBI-365996;
CC       P23443:RPS6KB1; NbExp=2; IntAct=EBI-296087, EBI-1775921;
CC       Q15047:SETDB1; NbExp=9; IntAct=EBI-296087, EBI-79691;
CC       Q96EB6:SIRT1; NbExp=5; IntAct=EBI-296087, EBI-1802965;
CC       Q13485:SMAD4; NbExp=2; IntAct=EBI-296087, EBI-347263;
CC       Q13043:STK4; NbExp=13; IntAct=EBI-296087, EBI-367376;
CC       P56279:TCL1A; NbExp=3; IntAct=EBI-296087, EBI-749995;
CC       Q9NYB0:TERF2IP; NbExp=2; IntAct=EBI-296087, EBI-750109;
CC       Q92547:TOPBP1; NbExp=2; IntAct=EBI-296087, EBI-308302;
CC       P08670:VIM; NbExp=29; IntAct=EBI-296087, EBI-353844;
CC       P03165:X (xeno); NbExp=3; IntAct=EBI-296087, EBI-7683985;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane.
CC       Note=Nucleus after activation by integrin-linked protein kinase 1
CC       (ILK1). Nuclear translocation is enhanced by interaction with
CC       TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its
CC       localization to the cell membrane where it is targeted for further
CC       phosphorylations on Thr-308 and Ser-473 leading to its activation
CC       and the activated form translocates to the nucleus. Colocalizes
CC       with WDFY2 in intracellular vesicles (PubMed:16792529).
CC       {ECO:0000269|PubMed:16792529}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P31749-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P31749-2; Sequence=VSP_056180;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in prostate cancer and levels
CC       increase from the normal to the malignant state (at protein
CC       level). Expressed in all human cell types so far analyzed. The
CC       Tyr-176 phosphorylated form shows a significant increase in
CC       expression in breast cancers during the progressive stages i.e.
CC       normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS),
CC       invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM)
CC       stages. {ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:17932490,
CC       ECO:0000269|PubMed:20333297}.
CC   -!- DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-
CC       trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-
CC       kinase alpha (PIK3CA) activity results in its targeting to the
CC       plasma membrane. The PH domain mediates interaction with TNK2 and
CC       Tyr-176 is also essential for this interaction.
CC   -!- DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4.
CC   -!- PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activating
CC       phosphorylation at Thr-308 via disrupting the interaction between
CC       AKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probably
CC       interferes with phosphorylation at this site.
CC       {ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,
CC       ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,
CC       ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,
CC       ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,
CC       ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,
CC       ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,
CC       ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.
CC   -!- PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required
CC       for full activity. Activated TNK2 phosphorylates it on Tyr-176
CC       resulting in its binding to the anionic plasma membrane
CC       phospholipid PA. This phosphorylated form localizes to the cell
CC       membrane, where it is targeted by PDPK1 and PDPK2 for further
CC       phosphorylations on Thr-308 and Ser-473 leading to its activation.
CC       Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylation
CC       by PDPK1. Phosphorylated at Thr-308 and Ser-473 by IKBKE and TBK1.
CC       Ser-473 phosphorylation is enhanced by interaction with AGAP2
CC       isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focal
CC       cortical dysplasias with Taylor-type balloon cells. Ser-473
CC       phosphorylation is enhanced by signaling through activated FLT3.
CC       Dephosphorylated at Thr-308 and Ser-473 by PP2A phosphatase. The
CC       phosphorylated form of PPP2R5B is required for bridging AKT1 with
CC       PP2A phosphatase. Ser-473 is dephosphorylated by CPPED1, leading
CC       to termination of signaling. {ECO:0000269|PubMed:12149249,
CC       ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15047712,
CC       ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983,
CC       ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494,
CC       ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595,
CC       ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307,
CC       ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:8978681,
CC       ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715}.
CC   -!- PTM: Ubiquitinated via 'Lys-48'-linked polyubiquitination by
CC       ZNRF1, leading to its degradation by the proteasome (By
CC       similarity). Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-
CC       linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1
CC       ubiquitination is critical for phosphorylation and activation.
CC       When ubiquitinated, it translocates to the plasma membrane, where
CC       it becomes phosphorylated. When fully phosphorylated and
CC       translocated into the nucleus, undergoes 'Lys-48'-
CC       polyubiquitination catalyzed by TTC3, leading to its degradation
CC       by the proteasome. Also ubiquitinated by TRIM13 leading to its
CC       proteasomal degradation. Phosphorylated, undergoes 'Lys-48'-linked
CC       polyubiquitination preferentially at Lys-284 catalyzed by MUL1,
CC       leading to its proteasomal degradation. {ECO:0000250,
CC       ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20059950,
CC       ECO:0000269|PubMed:21333377, ECO:0000269|PubMed:22410793}.
CC   -!- PTM: Acetylated on Lys-14 and Lys-20 by the histone
CC       acetyltransferases EP300 and KAT2B. Acetylation results in reduced
CC       phosphorylation and inhibition of activity. Deacetylated at Lys-14
CC       and Lys-20 by SIRT1. SIRT1-mediated deacetylation relieves the
CC       inhibition. {ECO:0000269|PubMed:21775285}.
CC   -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy
CC       originating from breast epithelial tissue. Breast neoplasms can be
CC       distinguished by their histologic pattern. Invasive ductal
CC       carcinoma is by far the most common type. Breast cancer is
CC       etiologically and genetically heterogeneous. Important genetic
CC       factors have been indicated by familial occurrence and bilateral
CC       involvement. Mutations at more than one locus can be involved in
CC       different families or even in the same case.
CC       {ECO:0000269|PubMed:17611497}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of
CC       the large intestine (the colon) and the rectum. Genetic
CC       alterations are often associated with progression from
CC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk
CC       factors for cancer of the colon and rectum include colon polyps,
CC       long-standing ulcerative colitis, and genetic family history.
CC       Note=The gene represented in this entry may be involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Note=Genetic variations in AKT1 may play a role in
CC       susceptibility to ovarian cancer.
CC   -!- DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highly
CC       variable, severe disorder of asymmetric and disproportionate
CC       overgrowth of body parts, connective tissue nevi, epidermal nevi,
CC       dysregulated adipose tissue, and vascular malformations. Many
CC       features of Proteus syndrome overlap with other overgrowth
CC       syndromes. {ECO:0000269|PubMed:18954143,
CC       ECO:0000269|PubMed:21793738}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowden
CC       syndrome, a hamartomatous polyposis syndrome with age-related
CC       penetrance. Cowden syndrome is characterized by hamartomatous
CC       lesions affecting derivatives of ectodermal, mesodermal and
CC       endodermal layers, macrocephaly, facial trichilemmomas (benign
CC       tumors of the hair follicle infundibulum), acral keratoses,
CC       papillomatous papules, and elevated risk for development of
CC       several types of malignancy, particularly breast carcinoma in
CC       women and thyroid carcinoma in both men and women. Colon cancer
CC       and renal cell carcinoma have also been reported. Hamartomas can
CC       be found in virtually every organ, but most commonly in the skin,
CC       gastrointestinal tract, breast and thyroid.
CC       {ECO:0000269|PubMed:23246288}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. RAC subfamily. {ECO:0000305}.
CC   -!- CAUTION: In light of strong homologies in the primary amino acid
CC       sequence, the 3 AKT kinases were long surmised to play redundant
CC       and overlapping roles. More recent studies has brought into
CC       question the redundancy within AKT kinase isoforms and instead
CC       pointed to isoform specific functions in different cellular events
CC       and diseases. AKT1 is more specifically involved in cellular
CC       survival pathways, by inhibiting apoptotic processes; whereas AKT2
CC       is more specific for the insulin receptor signaling pathway.
CC       Moreover, while AKT1 and AKT2 are often implicated in many aspects
CC       of cellular transformation, the 2 isoforms act in a complementary
CC       opposing manner. The role of AKT3 is less clear, though it appears
CC       to be predominantly expressed in brain. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AKT1ID355ch14q32.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M63167; AAA36539.1; -; mRNA.
DR   EMBL; AF283830; AAL55732.1; -; Genomic_DNA.
DR   EMBL; AF283819; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283820; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283821; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283822; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283823; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283824; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283825; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283826; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283827; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283828; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283829; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AK299310; BAH12997.1; -; mRNA.
DR   EMBL; AK314256; BAG36922.1; -; mRNA.
DR   EMBL; AB451242; BAG70056.1; -; mRNA.
DR   EMBL; AB451367; BAG70181.1; -; mRNA.
DR   EMBL; AL583722; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590327; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000479; AAH00479.1; -; mRNA.
DR   EMBL; BC084538; AAH84538.1; -; mRNA.
DR   EMBL; X61037; CAA43372.1; -; mRNA.
DR   CCDS; CCDS9994.1; -. [P31749-1]
DR   PIR; A39360; A39360.
DR   RefSeq; NP_001014431.1; NM_001014431.1. [P31749-1]
DR   RefSeq; NP_001014432.1; NM_001014432.1. [P31749-1]
DR   RefSeq; NP_005154.2; NM_005163.2. [P31749-1]
DR   RefSeq; XP_005267458.1; XM_005267401.1. [P31749-1]
DR   UniGene; Hs.525622; -.
DR   PDB; 1H10; X-ray; 1.40 A; A=1-123.
DR   PDB; 1UNP; X-ray; 1.65 A; A=1-121.
DR   PDB; 1UNQ; X-ray; 0.98 A; A=1-123.
DR   PDB; 1UNR; X-ray; 1.25 A; A=1-123.
DR   PDB; 2UVM; X-ray; 1.94 A; A=1-123.
DR   PDB; 2UZR; X-ray; 1.94 A; A=1-123.
DR   PDB; 2UZS; X-ray; 2.46 A; A=1-123.
DR   PDB; 3CQU; X-ray; 2.20 A; A=144-480.
DR   PDB; 3CQW; X-ray; 2.00 A; A=144-480.
DR   PDB; 3MV5; X-ray; 2.47 A; A=144-480.
DR   PDB; 3MVH; X-ray; 2.01 A; A=144-480.
DR   PDB; 3O96; X-ray; 2.70 A; A=2-443.
DR   PDB; 3OCB; X-ray; 2.70 A; A/B=144-480.
DR   PDB; 3OW4; X-ray; 2.60 A; A/B=144-480.
DR   PDB; 3QKK; X-ray; 2.30 A; A=144-480.
DR   PDB; 3QKL; X-ray; 1.90 A; A=144-480.
DR   PDB; 3QKM; X-ray; 2.20 A; A=144-480.
DR   PDB; 4EJN; X-ray; 2.19 A; A=2-446.
DR   PDB; 4EKK; X-ray; 2.80 A; A/B=144-480.
DR   PDB; 4EKL; X-ray; 2.00 A; A=144-480.
DR   PDB; 4GV1; X-ray; 1.49 A; A=144-480.
DR   PDB; 5KCV; X-ray; 2.70 A; A=2-446.
DR   PDBsum; 1H10; -.
DR   PDBsum; 1UNP; -.
DR   PDBsum; 1UNQ; -.
DR   PDBsum; 1UNR; -.
DR   PDBsum; 2UVM; -.
DR   PDBsum; 2UZR; -.
DR   PDBsum; 2UZS; -.
DR   PDBsum; 3CQU; -.
DR   PDBsum; 3CQW; -.
DR   PDBsum; 3MV5; -.
DR   PDBsum; 3MVH; -.
DR   PDBsum; 3O96; -.
DR   PDBsum; 3OCB; -.
DR   PDBsum; 3OW4; -.
DR   PDBsum; 3QKK; -.
DR   PDBsum; 3QKL; -.
DR   PDBsum; 3QKM; -.
DR   PDBsum; 4EJN; -.
DR   PDBsum; 4EKK; -.
DR   PDBsum; 4EKL; -.
DR   PDBsum; 4GV1; -.
DR   PDBsum; 5KCV; -.
DR   ProteinModelPortal; P31749; -.
DR   SMR; P31749; -.
DR   BioGrid; 106710; 291.
DR   DIP; DIP-24269N; -.
DR   IntAct; P31749; 149.
DR   MINT; MINT-203775; -.
DR   STRING; 9606.ENSP00000270202; -.
DR   BindingDB; P31749; -.
DR   ChEMBL; CHEMBL4282; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB01169; Arsenic trioxide.
DR   GuidetoPHARMACOLOGY; 1479; -.
DR   iPTMnet; P31749; -.
DR   PhosphoSitePlus; P31749; -.
DR   BioMuta; AKT1; -.
DR   DMDM; 60391226; -.
DR   EPD; P31749; -.
DR   MaxQB; P31749; -.
DR   PaxDb; P31749; -.
DR   PeptideAtlas; P31749; -.
DR   PRIDE; P31749; -.
DR   DNASU; 207; -.
DR   Ensembl; ENST00000349310; ENSP00000270202; ENSG00000142208. [P31749-1]
DR   Ensembl; ENST00000402615; ENSP00000385326; ENSG00000142208. [P31749-1]
DR   Ensembl; ENST00000407796; ENSP00000384293; ENSG00000142208. [P31749-1]
DR   Ensembl; ENST00000554581; ENSP00000451828; ENSG00000142208. [P31749-1]
DR   Ensembl; ENST00000554848; ENSP00000451166; ENSG00000142208. [P31749-1]
DR   Ensembl; ENST00000555528; ENSP00000450688; ENSG00000142208. [P31749-1]
DR   GeneID; 207; -.
DR   KEGG; hsa:207; -.
DR   UCSC; uc001ypk.4; human. [P31749-1]
DR   CTD; 207; -.
DR   DisGeNET; 207; -.
DR   GeneCards; AKT1; -.
DR   GeneReviews; AKT1; -.
DR   HGNC; HGNC:391; AKT1.
DR   HPA; CAB003765; -.
DR   HPA; HPA002891; -.
DR   MalaCards; AKT1; -.
DR   MIM; 114480; phenotype.
DR   MIM; 114500; phenotype.
DR   MIM; 164730; gene.
DR   MIM; 176920; phenotype.
DR   MIM; 615109; phenotype.
DR   neXtProt; NX_P31749; -.
DR   OpenTargets; ENSG00000142208; -.
DR   Orphanet; 201; Cowden syndrome.
DR   Orphanet; 744; Proteus syndrome.
DR   PharmGKB; PA24684; -.
DR   eggNOG; KOG0598; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00860000133668; -.
DR   HOGENOM; HOG000233033; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P31749; -.
DR   KO; K04456; -.
DR   OMA; QDDSMES; -.
DR   OrthoDB; EOG091G06FF; -.
DR   PhylomeDB; P31749; -.
DR   TreeFam; TF102004; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; R-HSA-1445148; Translocation of GLUT4 to the plasma membrane.
DR   Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation.
DR   Reactome; R-HSA-165159; mTOR signalling.
DR   Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network.
DR   Reactome; R-HSA-203615; eNOS activation.
DR   Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-450385; Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA.
DR   Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1.
DR   Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs.
DR   SABIO-RK; P31749; -.
DR   SignaLink; P31749; -.
DR   SIGNOR; P31749; -.
DR   ChiTaRS; AKT1; human.
DR   EvolutionaryTrace; P31749; -.
DR   GeneWiki; AKT1; -.
DR   GenomeRNAi; 207; -.
DR   PMAP-CutDB; P31749; -.
DR   PRO; PR:P31749; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000142208; -.
DR   CleanEx; HS_AKT1; -.
DR   ExpressionAtlas; P31749; baseline and differential.
DR   Genevisible; P31749; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0036064; C:ciliary basal body; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0098794; C:postsynapse; IEA:GOC.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0005819; C:spindle; IEA:Ensembl.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0071889; F:14-3-3 protein binding; IPI:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISS:BHF-UCL.
DR   GO; GO:0032794; F:GTPase activating protein binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016301; F:kinase activity; IDA:MGI.
DR   GO; GO:0030235; F:nitric-oxide synthase regulator activity; IMP:BHF-UCL.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0043325; F:phosphatidylinositol-3,4-bisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0005080; F:protein kinase C binding; IEA:Ensembl.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IEA:Ensembl.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0006924; P:activation-induced cell death of T cells; IMP:MGI.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0008637; P:apoptotic mitochondrial changes; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; TAS:UniProtKB.
DR   GO; GO:0030030; P:cell projection organization; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IMP:CAFA.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IEA:Ensembl.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0097011; P:cellular response to granulocyte macrophage colony-stimulating factor stimulus; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IMP:BHF-UCL.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IMP:UniProtKB.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IMP:CAFA.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0099565; P:chemical synaptic transmission, postsynaptic; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0031018; P:endocrine pancreas development; TAS:Reactome.
DR   GO; GO:0072655; P:establishment of protein localization to mitochondrion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0097194; P:execution phase of apoptosis; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007281; P:germ cell development; IEA:Ensembl.
DR   GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0015758; P:glucose transport; IEA:Ensembl.
DR   GO; GO:0005978; P:glycogen biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0060709; P:glycogen cell differentiation involved in embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0030212; P:hyaluronan metabolic process; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IMP:CAFA.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0035655; P:interleukin-18-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:MGI.
DR   GO; GO:0060716; P:labyrinthine layer blood vessel development; IEA:Ensembl.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0072656; P:maintenance of protein location in mitochondrion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0060644; P:mammary gland epithelial cell differentiation; TAS:UniProtKB.
DR   GO; GO:0001893; P:maternal placenta development; IEA:Ensembl.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:BHF-UCL.
DR   GO; GO:0045792; P:negative regulation of cell size; IEA:Ensembl.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; ISS:UniProtKB.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IMP:BHF-UCL.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; TAS:BHF-UCL.
DR   GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IMP:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; IEA:Ensembl.
DR   GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL.
DR   GO; GO:1901215; P:negative regulation of neuron death; NAS:ParkinsonsUK-UCL.
DR   GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; NAS:BHF-UCL.
DR   GO; GO:0010748; P:negative regulation of plasma membrane long-chain fatty acid transport; IMP:BHF-UCL.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0100002; P:negative regulation of protein kinase activity by protein phosphorylation; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IMP:BHF-UCL.
DR   GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0038061; P:NIK/NF-kappaB signaling; IMP:CAFA.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; TAS:ProtInc.
DR   GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IMP:CAFA.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; ISS:BHF-UCL.
DR   GO; GO:0031659; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0032079; P:positive regulation of endodeoxyribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0090004; P:positive regulation of establishment of protein localization to plasma membrane; IMP:BHF-UCL.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0010763; P:positive regulation of fibroblast migration; IEA:Ensembl.
DR   GO; GO:0046326; P:positive regulation of glucose import; IMP:BHF-UCL.
DR   GO; GO:0010907; P:positive regulation of glucose metabolic process; IMP:BHF-UCL.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:1903721; P:positive regulation of I-kappaB phosphorylation; IMP:CAFA.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IMP:BHF-UCL.
DR   GO; GO:0046622; P:positive regulation of organ growth; IEA:Ensembl.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0010765; P:positive regulation of sodium ion transport; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:CAFA.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0030163; P:protein catabolic process; IEA:Ensembl.
DR   GO; GO:0000060; P:protein import into nucleus, translocation; IMP:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:Ensembl.
DR   GO; GO:1901976; P:regulation of cell cycle checkpoint; TAS:UniProtKB.
DR   GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0005979; P:regulation of glycogen biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome.
DR   GO; GO:0031641; P:regulation of myelination; IEA:Ensembl.
DR   GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0050999; P:regulation of nitric-oxide synthase activity; TAS:Reactome.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW.
DR   GO; GO:0034405; P:response to fluid shear stress; IMP:BHF-UCL.
DR   GO; GO:0032094; P:response to food; IEA:Ensembl.
DR   GO; GO:0060416; P:response to growth hormone; ISS:AgBase.
DR   GO; GO:0009408; P:response to heat; TAS:ProtInc.
DR   GO; GO:1990418; P:response to insulin-like growth factor stimulus; ISS:AgBase.
DR   GO; GO:0006979; P:response to oxidative stress; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   GO; GO:0021510; P:spinal cord development; IEA:Ensembl.
DR   GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0031929; P:TOR signaling; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0006412; P:translation; IEA:Ensembl.
DR   CDD; cd05594; STKc_PKB_alpha; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR034676; Akt1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Carbohydrate metabolism; Cell membrane;
KW   Complete proteome; Cytoplasm; Developmental protein; Disease mutation;
KW   Disulfide bond; Glucose metabolism; Glycogen biosynthesis;
KW   Glycogen metabolism; Glycoprotein; Isopeptide bond; Kinase; Membrane;
KW   Neurogenesis; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome;
KW   Serine/threonine-protein kinase; Sugar transport; Transferase;
KW   Translation regulation; Transport; Ubl conjugation.
FT   CHAIN         1    480       RAC-alpha serine/threonine-protein
FT                                kinase.
FT                                /FTId=PRO_0000085605.
FT   DOMAIN        5    108       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      150    408       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      409    480       AGC-kinase C-terminal.
FT   NP_BIND     156    164       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       14     19       Inositol-(1,3,4,5)-tetrakisphosphate
FT                                binding.
FT   REGION       23     25       Inositol-(1,3,4,5)-tetrakisphosphate
FT                                binding.
FT   REGION      228    230       Inhibitor binding.
FT   ACT_SITE    274    274       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      53     53       Inositol-(1,3,4,5)-tetrakisphosphate.
FT   BINDING      86     86       Inositol-(1,3,4,5)-tetrakisphosphate.
FT   BINDING     161    161       Inhibitor; via amide nitrogen.
FT   BINDING     179    179       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     230    230       Inhibitor; via amide nitrogen.
FT   BINDING     234    234       Inhibitor.
FT   BINDING     292    292       Inhibitor.
FT   MOD_RES      14     14       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21775285}.
FT   MOD_RES      20     20       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21775285}.
FT   MOD_RES     124    124       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     126    126       Phosphoserine; alternate.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     129    129       Phosphoserine; alternate.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     176    176       Phosphotyrosine; by TNK2.
FT                                {ECO:0000269|PubMed:20333297}.
FT   MOD_RES     308    308       Phosphothreonine; by IKKE, PDPK1 and
FT                                TBK1. {ECO:0000269|PubMed:15718470,
FT                                ECO:0000269|PubMed:18456494,
FT                                ECO:0000269|PubMed:20333297,
FT                                ECO:0000269|PubMed:20481595,
FT                                ECO:0000269|PubMed:21464307,
FT                                ECO:0000269|PubMed:8978681,
FT                                ECO:0000269|PubMed:9512493}.
FT   MOD_RES     448    448       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     450    450       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     473    473       Phosphoserine; by IKKE, MTOR and TBK1;
FT                                alternate. {ECO:0000269|PubMed:14761976,
FT                                ECO:0000269|PubMed:15047712,
FT                                ECO:0000269|PubMed:15718470,
FT                                ECO:0000269|PubMed:16266983,
FT                                ECO:0000269|PubMed:17013611,
FT                                ECO:0000269|PubMed:20333297,
FT                                ECO:0000269|PubMed:20978158,
FT                                ECO:0000269|PubMed:21464307,
FT                                ECO:0000269|PubMed:23799035,
FT                                ECO:0000269|PubMed:8978681,
FT                                ECO:0000269|PubMed:9736715}.
FT   MOD_RES     474    474       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12149249}.
FT   CARBOHYD    126    126       O-linked (GlcNAc) serine; alternate.
FT                                {ECO:0000269|PubMed:22629392}.
FT   CARBOHYD    129    129       O-linked (GlcNAc) serine; alternate.
FT                                {ECO:0000269|PubMed:22629392}.
FT   CARBOHYD    305    305       O-linked (GlcNAc) threonine.
FT                                {ECO:0000269|PubMed:22629392}.
FT   CARBOHYD    312    312       O-linked (GlcNAc) threonine.
FT                                {ECO:0000269|PubMed:22629392}.
FT   CARBOHYD    473    473       O-linked (GlcNAc) serine; alternate.
FT                                {ECO:0000250}.
FT   DISULFID     60     77       {ECO:0000269|PubMed:20886116}.
FT   DISULFID    296    310       {ECO:0000250}.
FT   CROSSLNK    284    284       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:22410793}.
FT   VAR_SEQ       1     62       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056180.
FT   VARIANT      17     17       E -> K (in PROTEUSS and breast cancer;
FT                                also detected in colorectal and ovarian
FT                                cancer; somatic mutation; results in
FT                                increased phosphorylation at T-308 and
FT                                higher basal ubiquitination; the mutant
FT                                protein is more efficiently recruited to
FT                                the plasma membrane; alters
FT                                phosphatidylinositiol phosphates lipid
FT                                specificity of the AKT1 PH domain;
FT                                dbSNP:rs121434592).
FT                                {ECO:0000269|PubMed:17611497,
FT                                ECO:0000269|PubMed:18954143,
FT                                ECO:0000269|PubMed:19713527,
FT                                ECO:0000269|PubMed:21793738}.
FT                                /FTId=VAR_055422.
FT   VARIANT      25     25       R -> C (in CWS6; dbSNP:rs397514644).
FT                                {ECO:0000269|PubMed:23246288}.
FT                                /FTId=VAR_069791.
FT   VARIANT     167    167       V -> A (in dbSNP:rs11555433).
FT                                /FTId=VAR_051617.
FT   VARIANT     435    435       T -> P (in CWS6; dbSNP:rs397514645).
FT                                {ECO:0000269|PubMed:23246288}.
FT                                /FTId=VAR_069792.
FT   MUTAGEN       8      8       K->R: Substantial reduction of
FT                                ubiquitination, phosphorylation at T-308
FT                                and S-473, AKT activation as well as
FT                                IGF1-induced membrane recruitment.
FT                                Decrease in ubiquitination and
FT                                phosphorylation at T-308 as well as
FT                                impaired association with the membrane;
FT                                when associated with K-17.
FT                                {ECO:0000269|PubMed:19713527}.
FT   MUTAGEN      14     14       K->A: Impairs interaction with
FT                                PtdIns(3,4,5)P3 and PtdIns(3,4)P2.
FT                                {ECO:0000269|PubMed:12176338,
FT                                ECO:0000269|PubMed:19713527,
FT                                ECO:0000269|PubMed:21775285}.
FT   MUTAGEN      14     14       K->Q: Substantial reduction of
FT                                phosphorylation at T-308 and S-473, loss
FT                                of AKT activation, and loss of binding to
FT                                PIP3 as well as IGF1-induced membrane
FT                                recruitment.
FT                                {ECO:0000269|PubMed:12176338,
FT                                ECO:0000269|PubMed:19713527,
FT                                ECO:0000269|PubMed:21775285}.
FT   MUTAGEN      14     14       K->R: Substantial reduction of
FT                                ubiquitination, phosphorylation at T-308
FT                                and S-473, AKT activation, loss of
FT                                binding to PIP3 as well as IGF1-induced
FT                                membrane recruitment.
FT                                {ECO:0000269|PubMed:12176338,
FT                                ECO:0000269|PubMed:19713527,
FT                                ECO:0000269|PubMed:21775285}.
FT   MUTAGEN      17     17       E->K: No effect on membrane localization.
FT                                Loss of membrane localization; when
FT                                associated with Q-20.
FT                                {ECO:0000269|PubMed:21775285}.
FT   MUTAGEN      20     20       K->Q: Substantial reduction of
FT                                phosphorylation at T-308 and S-473,
FT                                reduced AKT activation, and reduced
FT                                binding to PIP3 as well as IGF1-induced
FT                                membrane recruitment. Loss of membrane
FT                                localization; when associated with K-17.
FT                                {ECO:0000269|PubMed:21775285}.
FT   MUTAGEN      20     20       K->R: Slight increase of phosphorylation
FT                                at T-308 and S-473.
FT                                {ECO:0000269|PubMed:21775285}.
FT   MUTAGEN      25     25       R->A,C: Impairs interaction with
FT                                PtdIns(3,4,5)P3 and PtdIns(3,4)P2.
FT                                {ECO:0000269|PubMed:12176338}.
FT   MUTAGEN      86     86       R->A: Impairs interaction with
FT                                PtdIns(3,4,5)P3 and PtdIns(3,4)P2.
FT                                {ECO:0000269|PubMed:12176338}.
FT   MUTAGEN     176    176       Y->F: Significant loss of interaction
FT                                with TNK2. Loss of membrane localization.
FT                                Significant reduction in phosphorylation
FT                                on Ser-473.
FT                                {ECO:0000269|PubMed:20333297}.
FT   MUTAGEN     305    305       T->A: Reduces O-GlcNAc levels; Reduces O-
FT                                GlcNAc levels even more; when associated
FT                                with A-312.
FT                                {ECO:0000269|PubMed:22629392}.
FT   MUTAGEN     305    305       T->Y: Abolishes phosphorylation at Thr-
FT                                308. {ECO:0000269|PubMed:22629392}.
FT   MUTAGEN     308    308       T->D: 5-fold activation and 18-fold
FT                                activation; when associated with D-473.
FT                                {ECO:0000269|PubMed:12244301,
FT                                ECO:0000269|PubMed:8978681}.
FT   MUTAGEN     312    312       T->A: Reduces O-GlcNAc levels; Reduces O-
FT                                GlcNAc levels even more; when associated
FT                                with A-305.
FT                                {ECO:0000269|PubMed:22629392}.
FT   MUTAGEN     312    312       T->Y: Abolishes phosphorylation at Thr-
FT                                308. {ECO:0000269|PubMed:22629392}.
FT   MUTAGEN     473    473       S->D: 7-fold activation and 25-fold
FT                                activation; when associated with D-308.
FT                                {ECO:0000269|PubMed:12244301,
FT                                ECO:0000269|PubMed:8978681}.
FT   MUTAGEN     474    474       Y->F: 55% inhibition of activation.
FT                                {ECO:0000269|PubMed:12149249}.
FT   CONFLICT    173    174       GR -> A (in Ref. 7; CAA43372).
FT                                {ECO:0000305}.
FT   CONFLICT    202    202       L -> Q (in Ref. 7; CAA43372).
FT                                {ECO:0000305}.
FT   CONFLICT    212    212       A -> R (in Ref. 7; CAA43372).
FT                                {ECO:0000305}.
FT   CONFLICT    246    246       S -> A (in Ref. 7; CAA43372).
FT                                {ECO:0000305}.
FT   CONFLICT    409    409       A -> T (in Ref. 7; CAA43372).
FT                                {ECO:0000305}.
FT   CONFLICT    476    476       A -> P (in Ref. 7; CAA43372).
FT                                {ECO:0000305}.
FT   CONFLICT    478    478       G -> A (in Ref. 7; CAA43372).
FT                                {ECO:0000305}.
FT   CONFLICT    478    478       G -> S (in Ref. 1; AAA36539, 2; AAL55732,
FT                                3; BAG36922 and 4; BAG70056/BAG70181).
FT                                {ECO:0000305}.
FT   HELIX         2      4       {ECO:0000244|PDB:1UNQ}.
FT   STRAND        6     15       {ECO:0000244|PDB:1UNQ}.
FT   STRAND       17     19       {ECO:0000244|PDB:1UNQ}.
FT   STRAND       22     30       {ECO:0000244|PDB:1UNQ}.
FT   STRAND       33     40       {ECO:0000244|PDB:1UNQ}.
FT   HELIX        45     48       {ECO:0000244|PDB:1UNQ}.
FT   STRAND       52     56       {ECO:0000244|PDB:1UNQ}.
FT   STRAND       61     65       {ECO:0000244|PDB:1UNQ}.
FT   STRAND       67     69       {ECO:0000244|PDB:1UNQ}.
FT   STRAND       72     79       {ECO:0000244|PDB:1UNQ}.
FT   STRAND       82     89       {ECO:0000244|PDB:1UNQ}.
FT   HELIX        93    115       {ECO:0000244|PDB:1UNQ}.
FT   HELIX       147    149       {ECO:0000244|PDB:4GV1}.
FT   STRAND      150    158       {ECO:0000244|PDB:4GV1}.
FT   STRAND      160    169       {ECO:0000244|PDB:4GV1}.
FT   TURN        170    172       {ECO:0000244|PDB:4GV1}.
FT   STRAND      175    182       {ECO:0000244|PDB:4GV1}.
FT   HELIX       183    188       {ECO:0000244|PDB:4GV1}.
FT   HELIX       192    204       {ECO:0000244|PDB:4GV1}.
FT   STRAND      213    218       {ECO:0000244|PDB:4GV1}.
FT   STRAND      220    227       {ECO:0000244|PDB:4GV1}.
FT   HELIX       235    242       {ECO:0000244|PDB:4GV1}.
FT   HELIX       247    268       {ECO:0000244|PDB:4GV1}.
FT   HELIX       277    279       {ECO:0000244|PDB:4GV1}.
FT   STRAND      280    282       {ECO:0000244|PDB:4GV1}.
FT   STRAND      284    286       {ECO:0000244|PDB:4EJN}.
FT   STRAND      288    290       {ECO:0000244|PDB:4GV1}.
FT   STRAND      309    311       {ECO:0000244|PDB:3MVH}.
FT   HELIX       313    315       {ECO:0000244|PDB:4GV1}.
FT   HELIX       318    322       {ECO:0000244|PDB:4GV1}.
FT   HELIX       330    344       {ECO:0000244|PDB:4GV1}.
FT   HELIX       354    363       {ECO:0000244|PDB:4GV1}.
FT   HELIX       374    383       {ECO:0000244|PDB:4GV1}.
FT   HELIX       388    390       {ECO:0000244|PDB:4GV1}.
FT   TURN        396    398       {ECO:0000244|PDB:4GV1}.
FT   HELIX       399    403       {ECO:0000244|PDB:4GV1}.
FT   HELIX       406    408       {ECO:0000244|PDB:4GV1}.
FT   HELIX       413    417       {ECO:0000244|PDB:4GV1}.
FT   STRAND      430    433       {ECO:0000244|PDB:3MVH}.
FT   HELIX       440    443       {ECO:0000244|PDB:4GV1}.
FT   STRAND      464    466       {ECO:0000244|PDB:4GV1}.
FT   STRAND      473    475       {ECO:0000244|PDB:4GV1}.
SQ   SEQUENCE   480 AA;  55686 MW;  6EAFF4F8AD436714 CRC64;
     MSDVAIVKEG WLHKRGEYIK TWRPRYFLLK NDGTFIGYKE RPQDVDQREA PLNNFSVAQC
     QLMKTERPRP NTFIIRCLQW TTVIERTFHV ETPEEREEWT TAIQTVADGL KKQEEEEMDF
     RSGSPSDNSG AEEMEVSLAK PKHRVTMNEF EYLKLLGKGT FGKVILVKEK ATGRYYAMKI
     LKKEVIVAKD EVAHTLTENR VLQNSRHPFL TALKYSFQTH DRLCFVMEYA NGGELFFHLS
     RERVFSEDRA RFYGAEIVSA LDYLHSEKNV VYRDLKLENL MLDKDGHIKI TDFGLCKEGI
     KDGATMKTFC GTPEYLAPEV LEDNDYGRAV DWWGLGVVMY EMMCGRLPFY NQDHEKLFEL
     ILMEEIRFPR TLGPEAKSLL SGLLKKDPKQ RLGGGSEDAK EIMQHRFFAG IVWQHVYEKK
     LSPPFKPQVT SETDTRYFDE EFTAQMITIT PPDQDDSMEC VDSERRPHFP QFSYSASGTA
//
